uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. CART
7. LLY
8. TSLA
9. META
10. FICO

Go back to uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

uniQure BV (QURE) PT Raised to $72 at B.Riley/FBR

November 15, 2018 9:58 AM EST

B.Riley/FBR analyst Madhu Kumar raised the price target on uniQure BV (NASDAQ: QURE) to $72.00 (from $50.00) while maintaining a Buy rating.

... More

uniQure BV (QURE) PT Raised to $65 at Cantor Fitzgerald

November 15, 2018 9:36 AM EST

Cantor Fitzgerald analyst Elemer Piros raised the price target on uniQure BV (NASDAQ: QURE) to $65.00 (from $58.00) while maintaining a Overweight rating.

Piros commented, "This morning, uniQure announced initial top-line data from the Phase 2b dose-confirmation study of AMT-061 for the treatment of... More

uniQure BV (QURE) PT Raised to 'Street High' $76 at Leerink Partners

November 15, 2018 8:56 AM EST

Leerink Partners analyst Joseph Schwartz raised the price target on uniQure BV (NASDAQ: QURE) to a 'Street High' $76.00 (from $61.00) while maintaining an Outperform rating following AMT-061 data.

... More

uniQure (QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

November 15, 2018 7:20 AM EST

uniQure (NASDAQ: QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

... More